Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma

Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma

header-info

The Food and Drug Administration (FDA) has approved Adcetris® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.